Avaleht › Südamepuudulikkus › Texas › Houston
Südamepuudulikkus kliinilised uuringud linnas Houston, TX
36 uuringut haiguse Südamepuudulikkus jaoks otsivad osalejaid linnas Houston ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
VärbamineFaas 3
- Research Site, Houston
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
VärbamineFaas 3
- The Methodist Hospital Research Institute, Houston
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
VärbamineFaas 2
- East Texas Cardiology PA, Houston
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
VärbamineFaas 3
- Research Site, Houston
- Research Site, Houston
- Research Site, Humble · 17 mi kaugusel
BiVACOR® Total Artificial Heart Early Feasibility Study
Värbamine
- Texas Heart Institute / Baylor St. Luke's Medical Center, Houston
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
VärbamineFaas 3
- CHI St. Luke's Health Baylor College of Medicine Medical Center, Houston
A Study of LY3971297 in Participants With Heart Failure
VärbamineFaas 1
- Houston Methodist Hospital, Houston
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
VärbamineFaas 3
- East Texas Cardiology PA, Houston
- Biopharma Informatic, Houston
- Orion Medical, Houston
- ja veel 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
VärbamineFaas 3
- Research Site, Houston
- Research Site, Houston
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
VärbamineFaas 3
- CON-10085, Houston, TX, Houston
- Houston, TX Investigative Site CON-10320, Houston
Novel Technologies to Improve Echocardiographic Estimates of Left Ventricular Filling Pressure in Heart Failure Combined With Atrial Fibrillation
VärbamineVaatlusuuring
- Methodist DeBakey Heart and Vascular Center, Houston
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
VärbamineFaas 3
- Houston, TX Investigative Site 10085, Houston
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
Värbamine
- Houston Methodist Hospital, Houston
- Memorial Hermann-Texas Medical Center, Houston
- Texas Heart Institute at Baylor St. Luke's Medical Center, Houston
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
VärbamineFaas 2
- Local Institution - 151, Houston
- Local Institution - 157, Houston
- Local Institution - 163, Houston
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
VärbamineFaas 2/3
- Texas Children's Hospital ( Site 0039), Houston
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
VärbamineFaas 2
- Center for Advanced Heart Failure, Houston
Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs
VärbamineVaatlusuuring
- Texas Children's Hospital, Houston
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
Värbamine
- Texas Heart Institute, Houston
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
VärbamineVaatlusuuring
- Houston, Houston
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
VärbamineVaatlusuuring
- The Methodist Hospital, Methodist Cancer Cencer, Houston
- BI Research Center, Houston
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
VärbamineFaas 3
- Tenax Investigational Site, Houston
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
VärbamineFaas 3
- East Texas Cardiology PA, Houston
- Victorium Clinical Research, Houston
- Main Heart Clinic, Houston
- ja veel 1
CSP #2025 - Geriatric OUt-of-hospital Randomized MEal Trial in Heart Failure: Veterans Affairs (GOURMET-VA)
Värbamine
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Assessment of CCM in HF With Higher Ejection Fraction
Värbamine
- Baylor College of Medicine, Houston
- Houston Methodist, Houston
- Memorial Hermann Texas Medical Center, Houston
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
VärbamineFaas 3
- FIN-10085, Houston, TX, Houston
18F-mFBG Imaging for Myocardial Sympathetic Innervation
VärbamineFaas 2
- UT Health Houston, Houston
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
VärbamineFaas 3
- Texas Children's Hospital - Cardiology, Houston
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Värbamine
- Baylor/Texas Heart, Houston
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
VärbamineFaas 3
- Texas Children's Hospital - Cardiology, Houston
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Värbamine
- CHI St. Luke's Health Baylor College of Medicine Medical Center, Houston
- Houston Methodist, Houston
- UTHealth Memorial Hermann, Houston
Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED)
VärbamineVaatlusuuring
- Baylor College of Medicine, Houston
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
Värbamine
- Houston Healthcare Medical Center, Houston
Left vs Left Randomized Clinical Trial
Värbamine
- Baylor College of Medicine, Houston
Cardiogenic Shock Working Group Registry
VärbamineVaatlusuuring
- Houston Methodist Hospital, Houston
Study Assessing Left Ventricular Administration of a Genetic Medicine Directing Organ Regeneration in Heart Failure
VärbamineFaas 1
- Texas Heart Institute, Houston
HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry
VärbamineVaatlusuuring
- Houston Methodist DeBakey Heart and Vascular Center, Houston
Südamepuudulikkus uuringud teistes linnades
- New York City, NY51 uuringut
- Boston, MA44 uuringut
- Dallas, TX42 uuringut
- Cleveland, OH33 uuringut
- Chicago, IL31 uuringut
- Philadelphia, PA31 uuringut
- San Francisco, CA29 uuringut
- St. Louis, MO26 uuringut
- Durham, NC26 uuringut
- Kansas City, MO25 uuringut
- Atlanta, GA25 uuringut
- Baltimore, MD24 uuringut
Muud uuringud linnas Houston
- Mitteväikerakuline kopsuvähk145 uuringut
- Rinnavähk126 uuringut
- Vähk (kõik liigid)121 uuringut
- Metastaatiline vähk104 uuringut
- Käär- ja pärasoolevähk102 uuringut
- Munasarjavähk89 uuringut
- Äge müeloidne leukeemia85 uuringut
- Kopsuvähk78 uuringut
- Eesnäärmevähk76 uuringut
- Endomeetriumivähk68 uuringut
- Pankreasevähk61 uuringut
- Melanoom59 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.